ACC Congress coverage: the interventional cardiology perspective

Stay up to date with the latest advances from American College of Cardiology Scientific Sessions, viewed through the lens of interventional cardiology.
Explore concise take-home messages, expert reviews, and exclusive interviews covering Hotline Sessions, Guidelines, and Late-Breaking Trials of key relevance to daily interventional practice.

Filter By

35 results

Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive drugs: 3-month primary results from the TARGET BP I Randomized Trial

08 Apr 2024

Alessandro Sticchi interviews David E. Kandzari about the results of the Target Bp I Randomized Trial which he presented at ACC.24.

The trial reports mixed results on nerve ablation for high blood pressure with a modest but statistically significant difference in lowered blood pressure at 3 months,...

David Kandzari

Author

David Kandzari
Alessandro Sticchi

Author

Alessandro Sticchi
Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive drugs: 3-month primary results from the Target Bp I Randomized Trial

Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)

08 Apr 2024

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Author

Ali Nazmi Calik
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques

Coronary sinus reducer for the treatment of refractory angina: A randomised, placebo-controlled trial (ORBITA-COSMIC)

08 Apr 2024

Aaysha Cader interviews Rasha Al-Lamee and Michael Foley about the results of the ORBITA-COSMIC trial presented at ACC.24 in Atlanta.

Results showed that coronary sinus reducer relieved angina symptoms but lacked evidence of increased blood flow to the heart. While beneficial for refractory angina patients, its mechanism remains...

Rasha Al-Lamee

Author

Rasha Al-Lamee

Author

Aaysha Cader
Michael Foley

Author

Michael Foley
ORBITA-COSMIC: Coronary sinus reducer for the treatment of refractory angina

TAVI versus SAVR in patients at low to intermediate risk: One year outcomes of the randomized DEDICATE-DZHK6 Trial

08 Apr 2024

Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.

TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...

Luigi Biasco

Author

Luigi Biasco
Moritz Seiffert

Author

Moritz Seiffert
TAVI versus SAVR in patients at low to intermediate risk: One year outcomes of the randomized DEDICATE-DZHK6 Trial

Protein and exercise to reverse frailty in older men and women undergoing transcatheter aortic valve replacement: The PERFORM-TAVR Trial

08 Apr 2024

Panos Xaplanteris provides his take on the results of PERFORM-TAVR presented by Jonathan Afilalo at ACC.24 in Atlanta.

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris
PERFORM-TAVR: Protein and exercise to reverse frailty in older patients undergoing TAVR